Pharmacotherapy in type 2 diabetes, such as sulphonylureas, glitazones, and insulin, contributes to undesirable consequences like weight gain or the exacerbation of the severity of existing OSAS, thus increasing cardiovascular risks [6,10]. The gene discussed is INS; the disease is type 2 diabetes mellitus.